Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial.

Completed

• Conditions: 1. Respiratory syncytial virus bronchiolitis; <br />2. infant wheeze; <br />3. post-bronchiolitis wheeze.

• Registration Number: NL-OMON23199

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 452

Inclusion Criteria

1. Gestational age 32-35 weeks.

Exclusion Criteria

1. Severe congenital anomaly;

2. Congenital heart disease;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Number of wheezing days during the first year of life.

Secondary Outcome Measures

Name	Time	Method
1. Health-related quality of life at age 1,3 and 6 years;<br /><br>2. Asthmatic symptoms at age 3 and 6 years measured by questionnaires.